Press releases
- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Key statistics
On Tuesday, Kodiak Sciences Inc (K27:BER) closed at 2.86, 119.52% above the 52 week low of 1.30 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.74 |
---|---|
High | 2.86 |
Low | 2.74 |
Bid | -- |
Offer | -- |
Previous close | 2.86 |
Average volume | 20.00 |
---|---|
Shares outstanding | 52.53m |
Free float | 49.56m |
P/E (TTM) | -- |
Market cap | 157.08m USD |
EPS (TTM) | -4.44 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 19:30 BST.
More ▼